Excess of initial warrant fair value over private placement proceeds
-
-
0
0
Change in fair value of warrant liability
-
-
0
0
Transaction costs paid pursuant to private placement
-
-
0
0
Transaction costs paid upon exercise of warrants issued in private placement
-
-
0
0
Change in fair value of contingent consideration
6,574
-
0
0
Cash payable to tax authorities related to withholding shares to satisfy rsu withholding obligations
-
0
-
-
Contingent consideration paid pursuant to almatabio transaction
4,813
-
-
-
Lease early termination fee
-
-
0
-
Change in fair value of derivative liability
-1,010
480
-24,200
12,530
Deferred taxes
17
12
131
10
Other receivables
-
-
0
-
Prepaid expenses and other current assets
922
-228
4,774
236
Accounts payable
2,991
219
-337
-1,892
Accrued expenses and other current liabilities
6,625
-1,495
5,350
1,020
Lease liability, net
-16
-31
-63
-38
Net cash used in operating activities
-19,988
-17,691
-14,246
-16,365
Purchases of investments
353,801
-
19,099
23,761
Maturities of investments
-
-
21,500
10,500
Cash assumed from almatabio transaction
-
-
0
0
Sales and maturities of investments
23,876
25,505
-
-
Net cash used in investing activities
-329,925
25,505
2,401
-13,261
Proceeds from sale of common stock pursuant to atm program
-
-
14,762
-
Proceeds from sale of common stock and pre-funded warrants in an underwritten public offering, gross
431,315
-
-
-
Transaction costs paid pursuant to atm program
-
-
462
-
Transaction costs paid pursuant to sale of common stock and pre-funded warrants in an underwritten public offering
26,403
-
-
-
Proceeds from issuance of common stock pursuant to atm program, net
-
-
-
14,370
Proceeds from exercise of stock options
5,231
2,178
774
-
Cash paid related to withholding shares to satisfy rsu tax withholding obligations
0
779
0
1
Proceeds from issuance of common stock under employee stock purchase plan, net of cash paid related to withholding shares to satisfy tax withholding obligations
66
-
-17
0
Proceeds from private placement investment, gross
-
-
0
0
Transaction costs paid pursuant to private placement
-
-
0
0
Proceeds from exercise of warrants issued in private placement, gross
-
-
0
-
Transaction costs paid upon exercise of warrants issued in private placement
-
-
0
-
Net cash provided by (used in) financing activities
410,209
1,399
687
14,369
Increase (decrease) in cash, cash equivalents and restricted cash
60,296
9,213
-11,158
-15,257
Cash, cash equivalents, and restricted cash at beginning of period
25,318
16,105
27,263
134,696
Cash, cash equivalents, and restricted cash at end of period
85,614
-
-
-
Issuance of common stock pursuant to almatabio milestone buyout option
1,761
-
-
-
Cash and cash equivalents
85,382
-
-
-
Restricted cash, current
49
-
-
-
Restricted cash, non-current
183
-
-
-
Total cash, cash equivalents and restricted cash
85,614
25,318
16,105
27,263
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.